Logo image of NIVF

NEWGENIVF GROUP LTD-A (NIVF) Stock Fundamental Analysis

USA - NASDAQ:NIVF - VGG0544E3032 - Common Stock

1.16 USD
-0.03 (-2.52%)
Last: 10/28/2025, 2:44:46 PM
Fundamental Rating

1

NIVF gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 101 industry peers in the Health Care Providers & Services industry. NIVF may be in some trouble as it scores bad on both profitability and health. NIVF does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NIVF had negative earnings in the past year.
In the past year NIVF has reported a negative cash flow from operations.
NIVF Yearly Net Income VS EBIT VS OCF VS FCFNIVF Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 0 -1M -2M

1.2 Ratios

NIVF has a worse Return On Assets (-3.22%) than 62.38% of its industry peers.
NIVF has a Return On Equity (-4.40%) which is in line with its industry peers.
Industry RankSector Rank
ROA -3.22%
ROE -4.4%
ROIC N/A
ROA(3y)-0.84%
ROA(5y)N/A
ROE(3y)-1.23%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NIVF Yearly ROA, ROE, ROICNIVF Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 0 -2 -4 -6 -8

1.3 Margins

NIVF does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NIVF Yearly Profit, Operating, Gross MarginsNIVF Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023

More info and screens

1

2. Health

2.1 Basic Checks

The number of shares outstanding for NIVF remains at a similar level compared to 1 year ago.
Compared to 1 year ago, NIVF has a worse debt to assets ratio.
NIVF Yearly Shares OutstandingNIVF Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2K 4K 6K 8K 10K
NIVF Yearly Total Debt VS Total AssetsNIVF Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -0.66, we must say that NIVF is in the distress zone and has some risk of bankruptcy.
NIVF has a worse Altman-Z score (-0.66) than 82.18% of its industry peers.
A Debt/Equity ratio of 0.10 indicates that NIVF is not too dependend on debt financing.
NIVF has a better Debt to Equity ratio (0.10) than 75.25% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Altman-Z -0.66
ROIC/WACCN/A
WACCN/A
NIVF Yearly LT Debt VS Equity VS FCFNIVF Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 20M 40M 60M

2.3 Liquidity

A Current Ratio of 0.02 indicates that NIVF may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.02, NIVF is doing worse than 95.05% of the companies in the same industry.
NIVF has a Quick Ratio of 0.02. This is a bad value and indicates that NIVF is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of NIVF (0.02) is worse than 95.05% of its industry peers.
Industry RankSector Rank
Current Ratio 0.02
Quick Ratio 0.02
NIVF Yearly Current Assets VS Current LiabilitesNIVF Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 500K 1M 1.5M 2M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for NIVF have decreased strongly by -486.09% in the last year.
EPS 1Y (TTM)-486.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-591.54%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, NIVF will show a very strong growth in Earnings Per Share. The EPS will grow by 20.31% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2Y44.63%
EPS Next 3Y26.49%
EPS Next 5Y20.31%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NIVF Yearly Revenue VS EstimatesNIVF Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 50M 100M 150M
NIVF Yearly EPS VS EstimatesNIVF Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 2 4 6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NIVF. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NIVF Price Earnings VS Forward Price EarningsNIVF Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NIVF Per share dataNIVF EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60

4.3 Compensation for Growth

A more expensive valuation may be justified as NIVF's earnings are expected to grow with 26.49% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.63%
EPS Next 3Y26.49%

More info and screens

0

5. Dividend

5.1 Amount

NIVF does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEWGENIVF GROUP LTD-A

NASDAQ:NIVF (10/28/2025, 2:44:46 PM)

1.16

-0.03 (-2.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.3%
Inst Owner Change0%
Ins Owners0.25%
Ins Owner Change0%
Market Cap2.15M
Revenue(TTM)N/A
Net Income(TTM)-685500
AnalystsN/A
Price TargetN/A
Short Float %17.69%
Short Ratio0.75
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.14
P/tB 0.14
EV/EBITDA N/A
EPS(TTM)-76.6
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.46
FCFYN/A
OCF(TTM)-0.46
OCFYN/A
SpS0
BVpS8.43
TBVpS8.43
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -3.22%
ROE -4.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-0.84%
ROA(5y)N/A
ROE(3y)-1.23%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.02
Quick Ratio 0.02
Altman-Z -0.66
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-486.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-591.54%
EPS Next YN/A
EPS Next 2Y44.63%
EPS Next 3Y26.49%
EPS Next 5Y20.31%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-395.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-61.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-61.77%
OCF growth 3YN/A
OCF growth 5YN/A

NEWGENIVF GROUP LTD-A / NIVF FAQ

Can you provide the ChartMill fundamental rating for NEWGENIVF GROUP LTD-A?

ChartMill assigns a fundamental rating of 1 / 10 to NIVF.


Can you provide the valuation status for NEWGENIVF GROUP LTD-A?

ChartMill assigns a valuation rating of 1 / 10 to NEWGENIVF GROUP LTD-A (NIVF). This can be considered as Overvalued.


What is the profitability of NIVF stock?

NEWGENIVF GROUP LTD-A (NIVF) has a profitability rating of 0 / 10.